Medicinal Products

Flixabi

The medicinal product has been authorised by the European Commission (EC) via centralised procedure in all EU Member States, based on the European Medicines Agency (EMA) experts' opinion.

Name Flixabi
Active Substance infliksimab
Prescription na recept
Type of prescription ograničeni recept
ATC Code L04AB02
Medicinal product marketed in the Croatia Da
Summary of product characteristics (SmPC), labelling and package leaflet (PL) download
Link to the European Medicines Agency's (EMA) product information download
Link to the European Commission's (EC) decisions download
Educational materials
for patients / caregivers
Kartica s podsjenikom za bolesnika 102022

Direct Healthcare Professional Communication

Name Date Download
Pismo zdravstvenim radnicima o primjeni živih cjepiva u dojenčadi koja je in utero ili tijekom dojenja bila izložena infliksimabu (Flixabi, Inflectra, Remicade, Remsima i Zessly) 07.03.2022 Merck Sharp & Dohme d.o.o., Samsung Bioepis NL B.V., Pfizer Croatia d.o.o., Oktal Pharma d.o.o., Sandoz GmbH
Back